The colonization rate and associated factors of vancomycin-resistant enterococci among HIV infected individuals in resource-limited settings of Southwest Ethiopia: a comparative cross-sectional study Authors: Imamu Bulcha, Yared Nigusu, Sisay Teferi, Lemi Ushu, Tamiru Endalu, Gemechis Dereje, Tesfaye Kassa, Kedir Abdella Published: 2026 ABSTRACT AbstractIntroductionVancomycin-resistant enterococci (VRE) constitute a major global public health concern. These organisms can colonize the gastrointestinal (GI) tract for prolonged periods, ranging from months to years, and efforts to eradicate colonization are often only temporarily effective, with recurrence occurring within days or weeks. In immunocompromised individuals, particularly people living with HIV, VRE colonization may progress to clinically significant infection. Therefore, this study aimed to determine the prevalence of VRE colonization and identify associated risk factors among HIV-positive patients attending Mettu Karl Comprehensive Specialized Hospital.MethodsA comparative cross-sectional study was conducted from July to September 2023 among 308 participants. Socio-demographic and clinical data were collected using a pretested structured questionnaire and a standardized checklist. Stool samples were collected for the isolation and identification of Enterococci using standard microbiological methods. Antimicrobial susceptibility testing was performed using the Kirby–Bauer disk diffusion technique. Data were entered into Epi Data version 3.1 and analyzed using SPSS version 26. Bivariable and multivariable logistic regression analyses were employed to assess the association between presumptive VRE colonization and potential risk factors. Variables with adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were used to determine the strength of associations, and a p-value of ≤ 0.05 was considered statistically significant.ResultsEnterococci were found in 56.8% (175 out of 308) of participants, with 9.1% (16 of 175) identified as presumptive VRE. Among HIV-positive individuals, the presumptive VRE colonization rate was 11.2% (11 cases), compared to 6.5% (5 cases) in HIV-negative individuals. Overall, 46.9% of the enterococci isolates showed multidrug resistance (MDR).Being hospitalized within the past six months was significantly associated with presumptive VRE colonization: (AOR = 0.148; 95% CI: 0.031–0.707; p = 0.017).ConclusionPresumptive VRE colonization rates were 11.2% among HIV-positive individuals and 6.5% among HIV-negative individuals; however, this difference was not statistically significant. Recent hospitalization were significant risk factors. Therefore, stronger antibiotic stewardship and infection control practices are recommended for people living with HIV.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12866-026-05257-4.Keywords: Enterococci colonization, Vancomycin resistant enterococci, HIV, Ethiopia Introduction The increasing resistance of Enterococcus species to commonly used antibiotics varies considerably across different geographic regions. This variation is influenced by local habits in prescribing antimicrobial drugs, the way treatments are chosen without knowing the exact cause of infection, and the presence of resistant strains in the community. Additionally, the ability of these bacteria to cause serious illness and their responsiveness to various antibiotics may have changed over time. The misuse of antibiotics in various settings has greatly contributed to the development of antimicrobial resistance and the rise of multidrug-resistant (MDR) Enterococcus strains [1]. Vancomycin-resistant enterococci (VRE) have become a growing concern for healthcare professionals because they are easily passed on and can transfer genes that make them resistant to antibiotics [2]. VRE has been included in the World Health Organization’s “Global Priority List of Antibiotic-Resistant Bacteria” [3] Furthermore, the Centers for Disease Control and Prevention (CDC) has categorized VRE as a serious threat to public health [4]. Colonization of the gastrointestinal tract by VRE can occur without any symptoms and may lead to infection in individuals who are more vulnerable. These susceptible individuals include people living with HIV, those who are seriously ill, patients who stay in hospitals for extended periods, individuals residing in long-term care facilities, people who are in close contact with others who are colonized or infected with VRE, and patients staying in rooms that were previously occupied by such individuals [5, 6]. Colonization may also occur in settings with a high prevalence of presumptive VRE among patients [7]. In Ethiopia, antiretroviral therapy (ART) coverage has expanded, but routine surveillance for vancomycin-resistant enterococci (VRE) in HIV care settings remains limited. Therefore, this study aims to assess the prevalence of presumptive VRE colonization and the associated risk factors among HIV-positive individuals visiting Mettu Karl Comprehensive Specialized Hospital. Materials and methods Study design, period and setting The study was carried out at Mettu Karl Comprehensive Specialized Hospital, located in Mettu Town, about 600 km southwest of Addis Ababa, Ethiopia, between July 1 and September 30, 2023. The hospital serves an estimated 2.5 million people within its catchment area and functions as a referral center for patients from surrounding regions. It has various healthcare units, including ART clinics, as well as a general laboratory with multiple services. With a capacity of 214 beds, the hospital provides care to roughly 13,500 inpatients and 80,000 outpatients annually. Data from the ART clinic indicated that around 1,378 HIV-positive adult clients were receiving different HAART regimens at the facility. For this study, all HIV-positive individuals aged 18 years and above who attended the ART clinic were included, while those who were critically ill were excluded. Sampling technique A convenient sampling method was used to select participants until the required sample size was reached. The sample size was calculated using EPI INFO version 7.2.5.0, based on a double population proportion. A prevalence of 3.1% was considered for HIV-negative clients from a previous study [6] while 11.4% was taken for HIV-positive clients [8]. Using these prevalence rates, with 80% power, 95% confidence level, and a 1:1 ratio, the final sample size was determined to be 308 participants (154 HIV-positive and 154 HIV-negative clients). The dependent variable was the prevalence of presumptive Vancomycin-resistant Enterococci (VRE) colonization, while the independent variables included age, sex, educational status, comorbidities (such as diabetes mellitus, chronic lung disease, and chronic heart disease), length of hospital stay at the time of sample collection, complete blood count (CBC), CD4 count, viral load, history of antibiotic use, and history of catheterization. Data collection and laboratory processing Socio-demographic and clinical information was obtained through structured questionnaires administered via face-to-face interviews, while additional clinical data were extracted from patient records using a standard checklist (ANNEX I). An experienced laboratory technologist collected 5 ml of blood from each participant. HIV status was determined using a rapid test kit (STAT pack) in accordance with the current Ethiopian testing algorithm. For HIV-positive clients, CD4 counts and viral load measurements were performed using the BD FACS PRESTO system, while complete blood counts were analyzed with the Mindray BC 3000 machine. Isolation and identification of enterococci About 5–10 g of fecal specimen was collected from participant. The specimen was collected in a sterile wide-mouth screw-capped container and labeled with the unique sample number, date and time of collection. Immediately, it was delivered to laboratory (Mettu Karl Comprehensive specialized hospital Laboratory) for culturing within 30 min. The collected samples was kept in the refrigerator for 1–2 h if unprocessed immediately [5]. Sample was inoculated on sterile Bile Esculin Azide Agar media (BEAA) (Hardy Diagnostics, Santa Maria, USA) with and without vancomycin and incubated for 24–48 h at 35–37 °C. Growth of bacteria was checked by observing the media visually. Colonies was characterized by looking into the background (dark brown to black back ground with gray hallow colonies). The colonies were selected randomly for identification presumptively as enterococci using Gram staining and catalase tests, inoculating in to Brain Heart Infusion (BHI) broth containing 6.5% NaCl and incubated at 45 °C for 24–48 h. The growth was indicated by turbidity formation. Finally PYR test was conducted and the positive result was considered as enterococci [9]. The antimicrobial susceptibility testing of the isolates was performed by the Kirby Bauer disk diffusion technique as per the modified Clinical and Laboratory Standard Institute [10]. Briefly, the isolates were refreshed on to nutrient agar for 18–24 h and suspension of 3–5 selected colonies was prepared in 5 ml normal saline. The suspension was compared to a 0.5 McFarland standard [10]. A sterile cotton swab was used to streak the plates and the excess suspension was removed by gentle pressing and rotation of the swab against the inside wall surface of the tube. The swab was then used to distribute the bacteria evenly over the entire surface of Mueller Hinton agar (MHA). The inoculated plates were left at room temperature to dry for 3–5 min. The antibiotic disk (penicillin (10 IU), ampicillin (10 µg), ciprofloxacin (5 µg), erythromycin (15 µg), and chloramphenicol (30 µg)) were applied on the surface of Mueller- Hinton agar using disk dispenser. The plates were incubated at 37 °C for 24 h and the results were interpreted as Sensitive, Intermediate or Resistant according to the Clinical and Laboratory Standard Institute guideline [10]. VRE identification in this study was based on growth on vancomycin-supplemented BEAA and should therefore be considered presumptive. Lack of confirmatory susceptibility testing may have led to overestimation of true VRE prevalence. Data quality assurance The quality of the data was assured by translating questionnaire to local language, Afan Oromo and Amharic. Pretesting was done to check the quality of tools. The completeness of data was checked each day by principal investigator. The reliability of the laboratory results were assured by implementing quality control measures throughout the whole process of the laboratory work. All materials, equipment and procedures were adequately controlled. Pre-analytical, analytical and post analytical stages of quality assurance was assured. Sterility of culture media was tested by incubating 5% of the batch at 35–37 °C overnight and evaluated for possible contamination. The standard reference bacterial strains, S. aureus ATCC25923 (negative control) and E. faecalis ATCC 51,299 (positive control), were used. To normalize the density of inoculums of bacterial suspension for susceptibility testing, 0.5% McFarland standard was used [9]. In addition, 10% of the samples was checked by senior laboratory experts. Statistical analysis Data was checked for completeness, cleaned manually, entered in Epi Data software. Then data was transferred into Statistical Package for Social Science (SPSS) for analysis. Descriptive statistics (frequencies and cross tabulations) was used to summarize data. Logistic regression was computed to assess the association between dependent and independent variables. Odds ratio at 95% confidence interval and P-value was used to determine statistical significance of the association. P-value < 0.05 was considered as statistically significant. Ethics approval and consent to participate Ethical clearance was secured from Institutional Ethics Review Board, Institute of Health, Jimma University with ethics approval number Ref No THRPG1/854. All methods were carried out in accordance with relevant guidelines and regulations, including the Declaration of Helsinki. Permission was obtained from MKCSH administration. Written informed consent was obtained from each participants after explanation of the purpose of the study and procedure of sample collection. All the personal information of participants collected for the purpose of this study was kept confidential. The presence of drug resistant isolates was informed to ART clinic focal person in charge at MKCSH for the better management of the study participant. Operational definition MDR: Bacteria that are resistant to ≥ 3 antibiotics in different classes. Presumptive Vancomycin-resistant enterococci (VRE): are specific strains of enterococci that have grown on bile esculin azide agar (BEAA) containing 6 µg/mL vancomycin. Vancomycin-sensitive enterococci (VSE): are specific strains of enterococci that have not grown on bile esculin azide agar (BEAA) containing 6 µg/mL vancomycin. Leukocytosis/ High: having WBC count greater than 12,000/mm3. Leucopenia/Low: having WBC count less than 4,000/mm3. Thrombocytopenic/Low: a platelet count of < 100,000/ µL. Thrombocytosis/High: a platelet count of ˃ 450,000/ µL. Results Socio-demographic characteristics of study participants A total of 308 study participants were enrolled in this study, of which 59.1%( 182/308) were females. The mean age of the participant was 34.69 ± 11.77 with the range between 18 and 70 years. The mean age of study group (HIV positive participants was of 36.6 ± 10.84, with the range of 18 to 70 years whereas the average age for control group was 32.79 ± 12.39 with range from 18 to 70years (Table 1). Table 1The frequency of socio-demographic characteristics of HIV positive and negative clients (n = 308) at MKCSH from July to September 2023Socio-demographic characteristicsHIV statusTotal (n = 308)Number (%)Positive (n = 154)Number (%)Negative (n = 154)Number (%)SexFemale94 (61.0%)88 (57.1%)182 (59.1%)Male60 (39.0%)66 (42.9%)126 (40.9%)Age ( in year)18–2428 (18.2%)52 (33.8%)80 (26.0%)25–3431 (20.1%)36 (23.4%)67 (21.8%)35–4462 (40.3%)37 (24.0%)99 (32.1%)45–5425 (16.2%)14 (9.1%)39 (12.7%)> 548 (5.2%)15 (9.7%)23 (7.5%)Place of residenceUrban111 (72.1%)116 (75.3%)227 (73.7%)Rural43 (27.9%)38 (24.7%)81 (26.3%)Educational levelUnable to read and write15 (9.7%)19 (12.3%)34 (11.0%)Primary63 (40.9%)22 (14.3%)85 (27.6%)Secondary64 (41.6%)65 (42.2%)129 (41.9%)College and above12 (7.8%)48 (31.2%)60 (19.5%)Marital statusSingle28 (18.2%)46 (29.9%)74 (24.0%)Married85 (55.2%91 (59.1%)176 (57.1%)Widowed33 (21.4%)13 (8.4%)46 (14.9%)Divorced8 (5.2%)4 (2.6%)12 (3.9%) The frequency of socio-demographic characteristics of HIV positive and negative clients (n = 308) at MKCSH from July to September 2023 Clinical characteristics of study participants The clinical data showed that majority of the participants had normal whole blood count including WBC 85.1% (262/308), hemoglobin level 90.3% (278/308) and platelet 92.5% (285/308). Out of the HIV positive study participants 86.4% (133/154) had CD4 count > 350 and 89.0% (137/154) had viral load count target not detected (TND).More than half of the study participants had previous history of antibiotic treatment for ≥ two weeks, 61.7%(190/308) (Table 2). Table 2The distribution of clinical characteristics of HIV positive and negative clients (n = 308) at MKCSH from July to September 2023Clinical characteristicsHIV statusTotal (n = 308)Number (%)POSITIVE(n = 154)Number (%)NEGATIVE (n = 154)Number (%)Total WBCNormal133(86.4%)129(83.8%)262(85.1%)Leukopenia16(10.4%)9(5.8%)25(8.1%)Leukocytosis5(3.2%)16(10.4%)21(6.8%)Number of neutrophilNormal134(87.0%)132(85.7%)266(86.4%)Neutropenia7(4.5%)2(1.3%)9(2.9%)Neutrophilia13(8.4%)20(13.0%)33(10.7%)Hemoglobin levelNormal135(87.7%)143(92.9%)278(90.3%)Anemic14(9.1%)11(7.1%)25(8.1%)High5(3.2%)0(0.0%)5(1.6%)Platelet countNormal139(90.3%)146(94.8%)285(92.5%)Thrombocytopenia5(3.2%)2(1.3%)7(2.3%)Thrombocytosis10(6.5%)6(3.9%)16(5.2%)CD4 counta≤ 35021(13.6%)21(13.6%)> 350133(86.4%)133(86.4%)Viral load levelaTND137(89.0%)137(89.0%)≤ 1506(3.9%)6(3.9%)> 15011(7.1%)11(7.1%)Previous antibiotic treatmentNEVER5(3.2%)34(22.1%)39(12.7)For ≥ 2 weeks79(51.3%)111(72.1%)190(61.7%)For < 2 weeks70(45.5%)9(5.8%)79(25.6%)History of hospitalizationYES23(14.9%)46(29.9%)69(22.4%)NO131(85.1%)108(70.1%)239(77.6%)Comorbid conditionsYES9(5.8%)18(11.7%)27(8.8%)NO145(94.2%)136(88.3%)281(91.2%)History of catheterizationYES6(3.9%)3(1.9%)9(2.9%)NO148(96.1%)151(98.1%)299(97.1%)aFor only HIV positive participants The distribution of clinical characteristics of HIV positive and negative clients (n = 308) at MKCSH from July to September 2023 aFor only HIV positive participants Prevalence of Enterococci and presumptive VRE among HIV positive and HIV negative clients The overall Enterococci colonization rate was 56.8% (175/308). The colonization rate among study group was 63.6% (98/154), whereas it was 50.0%( 77/154) in control group (Fig. 1). The overall prevalence of enterococci colonization among HIV positive and negative clients (n = 308) at MKCSH from July to September 2023 From all 175 isolates, 9.1% (16/175) were presumptive VRE. The rate of presumptive VRE was 11.2% (11/98) in HIV positive people whereas it was 6.5% (5/77) among control. In this study, there was no statistically significant association between presumptive VRE and seropositivity of HIV (P-value = 0.287, OR = 1.821, 95% CI = 0.605–5.482) (Table 3). Although no statistically significant association was observed between HIV status and presumptive VRE colonization, this finding should be interpreted cautiously, as the study may have been underpowered to detect a true difference. The wide confidence intervals further suggest imprecision, and thus the absence of association does not necessarily imply absence of a biological effect. Table 3Prevalence of presumptive VRE colonization among HIV positive and negative clients at MKCSH from July to September 2023Enterococcus isolatedTotal(n = 175)Number (%)OR (95% CI)P-valueVRE (n = 16)Number (%)VSE (n = 159)Number (%)HIV status+ve11(11.2%)87(88.8%)98(100.0%)1.821(0.605-5.482)0.287-ve5(6.5%)72(93.5%)77(100.0%) Prevalence of presumptive VRE colonization among HIV positive and negative clients at MKCSH from July to September 2023 Antimicrobial resistant patterns of Enterococci to other antibiotics Among 175 Enterococci isolates tested for antimicrobial susceptibility pattern, 115(65.7%) were resistant to Penicillin. Penicillin resistant Enterococci in HIV positives were 62(63.3%) and 53(68.8%) among control group. Ampicillin was resisted by 118 (67.4%) Enterococci isolates, of which, 66(67.3%) from HIV positives and 52(67.5%) were from and HIV negatives. Sixty eight isolates (38.9%) were resistant to Ciprofloxacin, of which, 41(41.8%) and 27(35.1%) were from HIV positive and HIV negative, respectively. Erythromycin (p = 0.043) and Chloramphenicol (p = 0.013) resistance have showed statistically significant difference of resistance patterns between isolates among HIV positive and HIV negative clients. However, there was no statistically significant differences observed between HIV positive and HIV negative clients in resistance pattern for the antibiotics: penicillin, ampicillin, ciprofloxacin and vancomycin (Table 4). Table 4Antimicrobial resistance profile of Enterococci among HIV positive and HIV negative clients at MKCSH from July to September 2023HIV statusTotal(n = 175)Number (%)X2P-valuePositive(n = 98)Number (%)Negative(n = 77)Number (%)PenicillinResistant62(63.3%)53(68.8%)115(65.7%)0.5930.441AmpicillinResistant66(67.3%)52(67.5%)118(67.4%)0.0010.979CiprofloxacinResistant41(41.8%)27(35.1%)68(38.9%)0.8320.362ErythromycinResistant48(49%)26(33.8%)74(42.3%)4.089 0.043 * ChloramphenicolResistant28(28.6%)10(13%)38(21.7%)6.161 0.013 * VancomycinResistant11(11.2%)5(6.5%)16(9.1%)1.1620.281MDRResistant52(53.1%)30(39.0%)82(46.9%)3.4430.064*statistically significant (p < 0.05) Antimicrobial resistance profile of Enterococci among HIV positive and HIV negative clients at MKCSH from July to September 2023 *statistically significant (p < 0.05) From the total of Enterococci isolates, 129(73.7%) were resistant to one or more antibiotics, of those isolates, 9(5.14%), 39(22.3%), 10(5.7%), 51(29.1%), 17(9.7%) and 4(2.3%) were resistance to one, two, three, four, five and six antibiotics, respectively (Table 5). Table 5Profile of multidrug resistant enterococci isolates at MKCSH from July to September 2023Resistant patternCombination of antibioticsNo. (%) of isolates testedR3PEN/AMP, CIP, ERY 32 (39.0%) PEN, CIP, ERY 3 (3.7%) CIP, ERY, CHLO 1 (1.2%) AMP, CIP, ERY 2 (2.4%) AMP, ERY, CHLO 3 (3.7%) PEN/AMP, ERY, CHLO 6 (7.3%) PEN/AMP, CIP, CHLO 9 (11.0%) PEN/AMP, CIP, VAN 2 (2.4%) PEN/AMP, ERY, VAN 1 (1.2%) PEN, ERY, CHLO 1 (1.2%) R4PEN/AMP, CIP, ERY, CHLO 8 (9.8%) PEN, CIP, ERY, CHLO 1 (1.2%) PEN/AMP, CIP, ERY, VAN 6 (7.3%) PEN/AMP, ERY, CHLO, VAN 3 (3.7%) R5PEN/AMP, ERY, CIP, CHLO, VAN 4(4.9%) Total MDR 82 (100%) R3 = Isolates resistant to 3 different classes of antibioticsR4 = Isolates resistant to 4 different classes of antibioticsR5 = Isolates resistant to 5 different classes of antibiotics Profile of multidrug resistant enterococci isolates at MKCSH from July to September 2023 R3 = Isolates resistant to 3 different classes of antibiotics R4 = Isolates resistant to 4 different classes of antibiotics R5 = Isolates resistant to 5 different classes of antibiotics In this study, multidrug resistance, defined as non-susceptibility to at least one agent in three or more antimicrobial classes, was observed in 82 of 175 enterococci isolates (46.9%) (Fig. 2). Profile of antimicrobial resistance and multidrug resistant enterococci isolates among HIV positive and negative clients at MKCSH from July to September 2023. X-axis = Resistance categories. Y-axis = Percent of the resistant isolates. R3 = Isolates resistant to 3 different classes of antibiotics. R4 = Isolates resistant to 4 different classes of antibiotics. R5 = Isolates resistant to 5 different classes of antibiotics All isolates of presumptive VRE, 16 (100.0%) were multidrug resistant and all isolates of VRE in HIV positive and HIV negative clients were resistant to Penicillin and Ampicillin (Table 6). Table 6Presumptive VRE (n = 16) isolates resistant patterns among HIV positive and HIV negative clients at MKCSH from July to September 2023Resistant to antibioticsHIV statusTotal(n = 16)Number (%)POSITIVE(n = 11)Number (%)NEGATIVE(n = 5)Number (%)Penicillin11(100.0%)5(100.0%)16(100.0%)Ampicillin11(100.0%)5(100.0%)16(100.0%)Ciprofloxacin8(72.7%)4(80.0%)12(75.0%)Erythromycin11(100.0%)3(60.0%)14(87.5%)Chloramphenicol7(63.6%)0(0.0%)7(43.8%)MDR11(100.0%)5(100.0%)16(100.0%) Presumptive VRE (n = 16) isolates resistant patterns among HIV positive and HIV negative clients at MKCSH from July to September 2023 Factors associated with the colonization of Vancomycin resistant enterococci among HIV positive clients at MKCSH 2023 Factors independently associated with presumptive VRE gut colonization on bivariable analysis, and fit into a multivariable logistic regression model were total WBC, number of neutrophil, hemoglobin level, platelet count, history of antibiotic treatment, history of hospitalization and comorbidity (P-value = 0.042) were significantly associated with colonization of presumptive VRE (p-value < 0.05). Although several variables were significant in bivariate analysis, only prolonged antibiotic exposure and one clinically relevant covariate were retained in the final model due to the limited number of outcome events (Table 7). Table 7Bivariate and multivariate analysis of independent variables with VRE colonization among HIV positive clients 2023Associated Risk factorsVRE colonizationP-valueCOR(95% CI)P-valueAOR(95% CI)ResistantSensitiveParticipant’s sexFemale6(10.5%)51(89.5%)0.7961.181(0.334–4.167)Male5(12.2%)36(87.8%)1Age of Respondent18–240(0.0%)21(100.0%)0.998NA25–343(13.0%)20(87.0%)0.1076.667(0.665–66.842)35–445(13.5%)32(86.5%)0.0946.400(0.727–56.323)45–541(7.7%)12(92.3%)0.08512.000(0.709-203.135)> 542(50.0%)2(50.0%)1Place of residenceUrban8(11.9%)59(88.1%)0.7420.790(0.195–3.208)Rural3(9.7%)28(90.3%)Educational levelUnable to read and write1(14.3%)6(85.7%)1Primary5(11.6%)38(88.4%)0.8411.267(0.125-12.802)Secondary3(7.1%)39(92.9%)0.5312.167(0.192-24.388)College and above2(33.3%)4(66.7%)0.4270.333(0.022–5.027)Marital statusSingle2(8.7%)21(91.3%)1Married5(9.8%)46(90.2%)0.8800.876(0.157–4.889)Widowed2(10.5%)17(89.5%)0.8410.810(0.103–6.362)Divorced2(40.0%)3(60.0%)0.0980.143(0.014–1.429)CD4 count≤ 3503(16.7%)15(83.3%)0.4231.800(0.427–7.588)> 3508(10.0%)72(90.0%)1Viral load levelTND8(9.5%)76(90.5%)1≤ 1501(20.0%)4(80.0%)0.4630.421(0.042–4.238)> 1502(22.2%)7(77.8%)0.2590.368(0.065–2.083)Total WBCNormal7(8.6%)74(91.4%)1Low2(15.4%)11(84.6%)0.4500.520(0.096–2.832)High2(50%)2(50%) 0.028 * 0.095(0.011–0.778)Number of neutrophilNormal7(8.1%)79(91.9%)1Low1(33.3%)2(66.7%)0.1790.177(0.014–2.207)High3(33.3%)6(66.7%) 0.033 * 0.1770(0.036-0.866)Hemoglobin levelNormal6(7.4%)75(92.6%)1Low4(28.6%)10(71.4%) 0.027 * 0.200(0.048–0.833)High1(33.3%)2(66.7%)0.1570.160(0.013–2.030)Platelet countNormal8(9.4%)77(90.6%)1Low2(50.0%)2(50.0%) 0.034 * 0.104(0.013–0.841)High1(11.1%)8(88.9%)0.8690.831(0.092–7.521)Previous antibiotic treatmentFor ≥ 2 weeks9(24.3%)28(75.7%) 0.006 * 9.482(1.920-46.817)0.1300.246 (0.040–1.509)For < 2 weeks2(3.3%)59(96.7%)11History of hospitalizationYes7(41.2%)10(58.8%) 0.000 * 13.475(3.343–54.316) 0.017 * 0.148 (0.031–0.707)No4(4.9%)77(95.1%)11Comorbid conditionsYes3(33.3%)6(66.7%) 0.042 * 5.063(1.059–24.205)No8(9.0%)81(91.0%)1History of catheterizationYes2(33.3%)4(66.7%)0.1024.611(0.739–28.787)No9(9.8%)83(90.2%)COR Crude Odds Ratio, AOR Adjusted Odds Ratio, 95%CI 95% Confidence Interval, N/A Not Applicable*statistically significant (p < 0.05) Bivariate and multivariate analysis of independent variables with VRE colonization among HIV positive clients 2023 COR Crude Odds Ratio, AOR Adjusted Odds Ratio, 95%CI 95% Confidence Interval, N/A Not Applicable *statistically significant (p < 0.05) The wide confidence intervals observed for some predictors indicate limited precision of the estimates, likely due to the small number of VRE isolates, and therefore these associations should be interpreted cautiously. Discussion Enterococci are opportunistic pathogens that can reside in the gastrointestinal tract for a prolonged time without causing any infection. They can also survive in hospital environments. Enterococci are naturally resistant to several antibiotic classes, and in recent years there has been a significant increase in the rates of acquired antimicrobial resistance (AMR) in both E. faecalis and E. faecium, including presumptive vancomycin-resistant enterococci (VRE) [11]. The emergence of presumptive vancomycin-resistant enterococci has become more common among individuals with weakened immune systems, including those who are HIV positive [12]. Therefore, there is a need for active monitoring and surveillance to prevent the spread and development of presumptive VRE. In this study, the overall prevalence of Enterococci colonization was found to be 56.8%. This result was similar to a previous study in the Netherlands, which reported 55% [13]. However, it was higher than the prevalence reported in Nigeria (5.9%) [14] and in Gondar, Ethiopia (6.2%) [15]. The difference may be due to the different types of samples used, as previous studies used clinical samples, while this study used stool samples. Since Enterococci are normal flora in the gastrointestinal tract and are subject to selective pressure from antibiotic use, especially in immunocompromised individuals, their colonization tends to increase over time. In this study, the participants were all HIV positive individuals who had been on repeated antibiotic therapy and had been hospitalized more frequently compared to participants in previous studies, who were mainly outpatients who did not use antibiotics as much and had lower hospitalization rates. On the other hand, the prevalence of Enterococci among HIV positive clients was found to be 63.6%, which aligns with studies conducted in Ethiopia, such as 63% [5] and 61.5% [8]. However, this result was lower than the 91.2% reported in a previous study from Gondar, Ethiopia [6]. The discrepancy might be attributed to the inclusion of all age groups in the earlier study, while this study focused on a specific age category. The overall prevalence of presumptive vancomycin-resistant Enterococci (VRE) in this study was 9.1%. This finding is consistent with studies from Turkey (9.85%) [16], , Singapore 9.3%, Germany 9.8%,Iran 9.4%,the United kingdom 9.2% [17], Taiwan 11.3% [18] and Gondar, Ethiopia 7% [15]. However, it was lower than the results from Benin (67.5%) [19], Iran (24.8%) [20] and India (19.6%) [21]. The lower rate of presumptive VRE in this study could be due to differences in the study participants and detection methods. The participants in previous studies were primarily hospitalized patients in the ICU, and the detection method used in Iran was molecular, which is more sensitive than the method used here. However, the current study reported a higher prevalence of presumptive VRE compared to studies conducted in the USA (4.2%) [22] and South Korea (4.5%) [23]. This difference may be explained by variation of study period and geographical locations. In this study, the prevalence of presumptive VRE among HIV positive clients was 11.2% (11 out of 98), which is in line with the findings from Arba Minch, Ethiopia (11.4%) [8]. However, it was higher than the 0% reported in California [24]. This difference could be due to variations in individual exposure to potential sources of transmission, such as contact with animals and the higher proportion of female participants in this study. Additionally, previous studies in California included more male participants. Since Enterococci are commonly found in the oropharynx, vagina, urethra, and skin of healthy individuals, there may be a higher carriage rate among females [25]. Antibiotic resistance patterns were also investigated for the isolated Enterococci. The penicillin resistance rate was 65.7%, which aligns with reports from Gondar, Ethiopia (66.7%) [15], ampicillin; 67.4%, this finding was more likely agreed with result reported from Iran 69.7% [26], Gondar Ethiopia 66.7% [15] and Arba Minch Ethiopia 69.9% [8], ciprofloxacin; 38.9%, in line with results reported from West Amhara Ethiopia 37.7% [5],Erythromycin; 42.3%, consistent with results from Brazil 45.7% [27] and West Amhara Ethiopia 42.7% [5], Chloramphenicol; 21.7% this was consistent with reports from Iran 23.6% [26], Saudi Arabia 22.7% [28] and Arba Minch, Ethiopia 21.1% [8]. Out of the 175 Enterococci isolates identified, 82 (46.9%) were found to be multidrug-resistant (MDR).This finding is consistent with a study from Arba Minch, Ethiopia (49.59%) [8]. However, it is lower than the rate reported from Jimma, Ethiopia (89.5%) [29]. The difference might be due to variations in study participants and the methods used for susceptibility testing. In Jimma, Ethiopia, the method used was minimum inhibitory concentration determined using E-test strips for vancomycin [29]. History of previous antibiotic use for more than two weeks (P = 0.043) and history of hospitalization in the last six months (P = 0.031) were found to be important risk factor. Similar findings were reported from Gondar, Ethiopia [15] where antibiotic exposure was shown to contribute to the emergence of VRE and the survival of Enterococci in the hospital environment due to their intrinsic resistance to several commonly used antibiotics and their ability to acquire resistance genes. However, CD4 + count, viral load level, total white blood cell count, number of neutrophils, hemoglobin level, platelet count, comorbid conditions, and a history of catheterization were not statistically significant risk factors for presumptive VRE (P > 0.05). This result is consistent with previous studies conducted in Taiwan [30], Brazil [27], Korea [23], West Amhara, Ethiopia [5] and Arba Minch, Ethiopia [8]. Limitation of the study The use of convenience sampling may introduce selection bias and limit the representativeness and generalizability of the findings. Other key limitation of this study is the absence of MIC determination and confirmatory methods such as agar dilution or molecular assays (e.g., vanA/vanB gene detection), which may affect the accuracy of VRE identification were not done due to resource limitation. The antibiotic panel was limited to agents available in our setting; important drugs such as linezolid and daptomycin were not included, which may limit the comprehensiveness of resistance profiling. Potential confounders such as intensity of healthcare exposure and prior colonization were not fully assessed, which may result in residual confounding of the observed associations. Additionally, the study may have been underpowered to detect a statistically significant association between HIV status and presumptive VRE carriage. The sample size calculation was based on an expected VRE prevalence of 3.1% among HIV-negative individuals; however, the observed prevalence in this group was higher (6.5%). This reduced the effective power to detect differences between comparison groups. Therefore, the absence of a statistically significant association should be interpreted cautiously, as it may reflect insufficient statistical power rather than the absence of a true biological relationship. Conclusion Although the prevalence of presumptive VRE was slightly higher among HIV-positive individuals compared to HIV-negative individuals, this difference was not statistically significant (p = 0.287), indicating that no definitive association could be established. Most of the isolates were resistance to one or more commonly used antibiotics in this study. Prevalence of presumptive VRE and MDR enterococci in the study area were high. This indicates rate of GIT colonization with presumptive VRE in HIV positive people is slightly high as compared to apparently healthy individuals. Hospitalization in the last six months was statistically associated with presumptive VRE colonization. Additionally, a colonization rate of approximately 11% may have implications for empiric antibiotic selection in febrile HIV patients in this setting, particularly among those with prior healthcare exposure. However, these suggestions should be considered preliminary given the presumptive nature of VRE identification and the imprecision of the effect estimates. Therefore, in resource-limited settings, implementation strategies should focus on strengthening antimicrobial stewardship through guideline-based prescribing, regular training of healthcare workers, and antibiotic use monitoring. In addition, reinforcing infection prevention measures such as hand hygiene, patient isolation where feasible, and routine surveillance of resistant organisms is essential. In addition health institutions should provide full service to HIV positive individuals, including microbiological susceptibility testing. Supplementary Information Supplementary Material 1. Acknowledgements We would like to thank those who were involved in this research. Abbreviations Antiretroviral therapy Bile esculin azide agar Brain heart infusion Center for disease control and prevention Clinical and laboratory standard institute Complete blood count Gastro intestinal highly active antiretroviral therapy Human immunodeficiency virus Intensive care unit Muller Hinton agar Mettu Karl comprehensive specialized hospital Methicillin resistant staphylococcus auras National committee for clinical laboratory standard Penicillin binding protein Surgical intensive care unit Standard operating procedure Statistical package for social science Target not detected Urinary tract infection Vancomycin resistant Enterococcus Vancomycin resistant Enterococcus faecium Vancomycin resistant Staphylococcus aureus Vancomycin sensitive Enterococcus World health organization Authors’ contributions All authors (IB, YN, ST, LU, TE, GD, TK and KA) carried out proposal development, data collection, data analysis and drafted the manuscript. All authors read and approved the final manuscript. Funding The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors received no specific funding for this work. Data availability The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate Ethical clearance was secured from Institutional Ethics Review Board, Institute of Health, Jimma University with ethics approval number Ref No THRPG1/854. All methods were carried out in accordance with relevant guidelines and regulations, including the Declaration of Helsinki. Permission was obtained from MKCSH administration. Written informed consent was obtained from each participants after explanation of the purpose of the study and procedure of sample collection. All the personal information of participants collected for the purpose of this study was kept confidential. The presence of drug resistant isolates was informed to ART clinic focal person in charge at MKCSH for the better management of the study participant. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.